Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Our findings suggest that the frequency of HER2 overexpression or amplification was low in Chinese CRC patients, and provide a rationale for further evaluation of HER2 in CRC based on the HERACLES criteria and the HER2 diagnostic criteria for gastroesophageal adenocarcinoma.
|
31720832 |
2020 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Sub-protocol Q.
|
31504139 |
2019 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Human epidermal growth factor receptor 2 (HER2) is expressed in some gastric and gastroesophageal junction adenocarcinomas.
|
30624589 |
2019 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Hepatoid adenocarcinomas showed relatively frequent expressions of HER2 (score 3+/2+: 21%/19%).
|
30946937 |
2019 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Mutations in erb-b2 receptor tyrosine kinase 2 (HER2) oncogene are observed in approximately 3% of lung adenocarcinomas or mixed tumors with adenocarcinoma component.
|
30825613 |
2019 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
This review provides up-to-date practical guidance to clinicians on accurate HER2 testing and interpretation of results in gastric/GEJ adenocarcinoma.
|
30928424 |
2019 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
For this double-blind, randomised, placebo-controlled, phase 3 trial done at 126 centres in 20 countries, we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and adequate organ function.
|
30718072 |
2019 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma.
|
31101074 |
2019 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The HER2 concordance rate between primary gastric adenocarcinomas and CB-MEs was 88.9% (40/45) (κ = - 0.056).
|
31477048 |
2019 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Although several molecular classifications have been proposed, precision medicine for HER2-amplified GEA patients still represents a challenge.
|
31046106 |
2019 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
We enrolled 26 patients with metastatic HER2-positive gastric or GE junction adenocarcinoma between February 2011 and June 2015.
|
30088161 |
2019 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The most recent brain metastases were HER2+ for 32% of patients: 2 of 3 esophageal squamous cell carcinomas, 3 of 10 esophageal adenocarcinomas (ACs), 3 of 14 colorectal ACs, and 1 of 1 pancreatic AC.
|
30373904 |
2019 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Compared with patients with adenocarcinoma only, those with ASC demonstrated profoundly worse disease-specific survival (5-year event-free rate, 34% vs. 6%; multivariate hazard ratio, 2.87 [95% confidence interval, 1.59-4.76]; P=0.0010) and overall survival (P=0.0027) that was independent of known prognostic factors and HER2 status.
|
30516569 |
2019 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Complete Remission of Metastatic HER2+ Oesophagogastric Junctional Adenocarcinoma under long-term Trastuzumab Treatment.
|
31826054 |
2019 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
We found recurrent somatic missense mutations in 22 genes (including PIK3CA, ERBB2, and GNAS) and a widespread APOBEC cytidine deaminase mutagenesis pattern (TCW motif) in both adenocarcinoma (ACC) and squamous cell carcinomas (SCCs).
|
31624127 |
2019 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Significance of HER2 protein expression and <i>HER2</i> gene amplification in colorectal adenocarcinomas.
|
31040898 |
2019 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Earlier, we showed that the targeted toxin DARPin-PE40 consisting of the HER2-specific non-immunoglobulin polypeptide (the targeting module) and a fragment of <i>Pseudomonas</i> exotoxin A (the toxic module) exhibits an antitumor effect <i>in vivo</i> against the HER2-positive adenocarcinoma xenograft.
|
29104782 |
2019 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Ion AmpliSeq Cancer Panel detected 9 potentially actionable variants in 29 adenocarcinomas that were wild type by the 8-gene panel testing (9 of 29, 31.0%) in the following genes: ERBB2 (3 of 29, 10.3%), STK11 (2 of 29, 6.8%), PTEN (2 of 29, 6.8%), FBXW7 (1 of 29, 3.4%), and BRAF G469A (1 of 29, 3.4%).
|
29219616 |
2018 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Trastuzumab® is used for human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma.
|
29277796 |
2018 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Only 2 AVCs (7.7%; both intestinal-type) showed a HER2 overexpression (both 2+), which corresponded to a HER2 gene amplification at CISH analysis.
|
29731265 |
2018 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
HER2 S310Y single site substitution was discovered in recent years and afatinib efficacy for adenocarcinoma patients harboring S310Y mutation has not been reported.
|
29561699 |
2018 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistance.
|
29318901 |
2018 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The use of biologics targeted to the human epidermal growth factor receptor 2 (HER2) protein is the latest addition to the armamentarium used to fight advanced gastric or gastro-oesophageal junction adenocarcinoma.
|
29439009 |
2018 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
To gain a better understanding of the concordance of IHC and FISH results at our institution, we identified all gastroesophageal adenocarcinomas at our institution tested for HER2 (n=125).
|
27153447 |
2018 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Brain metastasis in gastroesophageal adenocarcinoma and HER2 status.
|
29429124 |
2018 |